Start main page content
Factors associated with pulmonary impairment in HIV-infected South African adults

HIV-infected individuals have increased risk of developing obstructive lung disease (OLD). Studies from developed countries report high viral load, low CD4 counts, and anti-retroviral therapy (ART) to be associated with OLD; but these findings may not be generalizable to populations in resource-limited settings.

Read more...

Linking the global positioning system (GPS) to a personal digital assistant (PDA)

Linking the global positioning system (GPS) to a personal digital assistant (PDA) to support tuberculosis control in South Africa: a pilot study. In this proof of concept study, we compared the time taken to re-find a home comparing given residential addresses with a customised personalised digital assistant linked to a global positioning system (PDA/GPS) device. Additionally, we assessed the feasibility of using aerial photographs to locate homes.

Read more...

List of related publications

Breiman, R. F. et al. (2023) ‘Shifting the center of gravity for addressing the rising cancer disease burden in Africa: A rationale for African-based integrative infectious diseases and oncology research’, PLOS Global Public Health, 3(5), pp. 1–4. doi: 10.1371/journal.pgph.0001970

Publications by IDORI Associates and their teams

  1. Abdulla, N., Vincent, C. T. and Kaur, M. (2021) ‘Mechanistic Insights Delineating the Role of Cholesterol in Epithelial Mesenchymal Transition and Drug Resistance in Cancer’, Frontiers in Cell and Developmental Biology, 9. doi: 10.3389/fcell.2021.728325.
  2. Bloom, K. et al. (2013) ‘Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.’, Molecular therapy?: the journal of the American Society of Gene Therapy, 21(10), pp. 1889–1897. doi: 10.1038/mt.2013.170.
  3. Boua, P. R. et al. (2022) ‘Genetic associations with carotid intima-media thickness link to atherosclerosis with sex-specific effects in sub-Saharan Africans’, Nature Communications, 13(1), p. 855. doi: 10.1038/s41467-022-28276-x.
  4. Chengalroyen, M. D. et al. (2016) ‘Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis’, American Journal of Respiratory and Critical Care Medicine, 194(12), pp. 1532–1540. doi: 10.1164/rccm.201604-0769OC.
  5. Choudhury, A. et al. (2022) ‘Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits’, Nature Communications, 13(1), p. 2578. doi: 10.1038/s41467-022-30098-w.
  6. Cohen, C. et al. (2021) ‘Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study.’, The Lancet. Global health, 9(6), pp. e863–e874. doi: 10.1016/S2214-109X(21)00141-8.
  7. Cohen, C. et al. (2022) ‘SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.’, The Lancet. Infectious diseases, 22(6), pp. 821–834. doi: 10.1016/S1473-3099(22)00069-X.
  8. da Rocha, J. E. B. et al. (2021) ‘The Extent and Impact of Variation in ADME Genes in Sub-Saharan African Populations’, Frontiers in Pharmacology, 12. doi: 10.3389/fphar.2021.634016.
  9. Douillard, J.-Y. et al. (2013) ‘Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.’, The New England journal of medicine, 369(11), pp. 1023–1034. doi: 10.1056/NEJMoa1305275.
  10. du Plessis, T.-L., Abdulla, N. and Kaur, M. (2023) ‘The utility of 3D models to study cholesterol in cancer: Insights and future perspectives’, Frontiers in Oncology, 13. doi: 10.3389/fonc.2023.1156246.
  11. Ealand, C. et al. (2018) ‘Resuscitation-Promoting Factors Are Required for Mycobacterium smegmatis Biofilm Formation.’, Applied and environmental microbiology, 84(17). doi: 10.1128/AEM.00687-18.
  12. Ely, A. et al. (2021) ‘In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection.’, Advanced drug delivery reviews, 168, pp. 134–146. doi: 10.1016/j.addr.2020.05.010.
  13. Grossheim, L. et al. (2021) ‘Cancer and COVID-19 Experiences at African Cancer Centers: The Silver Lining.’, JCO global oncology, 7, pp. 410–415. doi: 10.1200/GO.20.00564.
  14. Gu, L. et al. (2019) ‘Targeting cellular cholesterol for anticancer therapy’, The FEBS Journal, 286(21), pp. 4192–4208. doi: https://doi.org/10.1111/febs.15018.
  15. Hayat, M. et al. (2021) ‘Genetic Susceptibility to Breast Cancer in Sub-Saharan African Populations.’, JCO global oncology, 7, pp. 1462–1471. doi: 10.1200/GO.21.00089.
  16. Hölzemer, A. et al. (2015) ‘Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.’, PLoS medicine, 12(11), pp. e1001900; discussion e1001900. doi: 10.1371/journal.pmed.1001900.
  17. Kairuz, D. et al. (2023) ‘Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.’, Pharmaceutics, 15(4). doi: 10.3390/pharmaceutics15041173.
  18. Kamp, M. et al. (2022) ‘Clinicians’ Perceptions towards Precision Medicine Tools for Cardiovascular Disease Risk Stratification in South Africa’, Journal of Personalized Medicine, 12(9). doi: 10.3390/jpm12091360.
  19. Kleynhans, J. et al. (2021) ‘Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study.’, PLoS medicine, 18(2), p. e1003537. doi: 10.1371/journal.pmed.1003537.
  20. Machowski, E. E. and Kana, B. D. (2017) ‘Genetic Mimetics of Mycobacterium tuberculosis and Methicillin-Resistant Staphylococcus aureus as Verification Standards for Molecular Diagnostics.’, Journal of clinical microbiology, 55(12), pp. 3384–3394. doi: 10.1128/JCM.01111-17.
  21. Maepa, M. B. et al. (2017) ‘Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs.’, Molecular therapy. Nucleic acids, 7, pp. 190–199. doi: 10.1016/j.omtn.2017.04.007.
  22. Marimani, M. D. et al. (2015) ‘Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.’, Journal of controlled release: official journal of the Controlled Release  Society, 209, pp. 198–206. doi: 10.1016/j.jconrel.2015.04.042.
  23. Moore, P. L. et al. (2012) ‘Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.’, Nature medicine, 18(11), pp. 1688–1692. doi: 10.1038/nm.2985.
  24. Moyes, J. et al. (2023) ‘The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016.’, BMC medicine, 21(1), p. 139. doi: 10.1186/s12916-023-02853-3.
  25. Moyo, T. et al. (2018) ‘Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.’, Journal of virology, 92(14). doi: 10.1128/JVI.02261-17.Moyo, T. et al. (2017) ‘Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies.’, Virology, 501, pp. 12–24. doi: 10.1016/j.virol.2016.10.026.
  26. Moyo-Gwete, T. et al. (2021) ‘SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.’, bioRxiv?: the preprint server for biology. United States. doi: 10.1101/2021.03.06.434193.
  27. Moyo-Gwete, T. et al. (2022) ‘Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.’, Journal of virology, 96(15), p. e0055822. doi: 10.1128/jvi.00558-22.
  28. Moyo-Gwete, T. et al. (2022) ‘Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms.’, Scientific reports, 12(1), p. 16473. doi: 10.1038/s41598-022-20141-7.
  29. Naidoo, K. K. et al. (2019) ‘Neutrophil Effector Functions Are Not Impaired in Duffy Antigen Receptor for Chemokines (DARC)-Null Black South Africans’, Frontiers in Immunology, 10. doi: 10.3389/fimmu.2019.00551.
  30. Nel, J. S. et al. (2018) ‘Endemic Mycoses in Solid Organ Transplant Recipients.’, Infectious disease clinics of North America, 32(3), pp. 667–685. doi: 10.1016/j.idc.2018.04.007.
  31. Nel, J. S. et al. (2020) ‘Southern African HIV Clinicians Society guidelines for solid organ transplantation in human immunodeficiency virus: An evidence-based framework for human immunodeficiency virus-positive donors and recipients.’, Southern African journal of HIV medicine, 21(1), p. 1133. doi: 10.4102/sajhivmed.v21i1.1133.
  32. Nel, J. S. et al. (2017) ‘Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review’, Clinical Infectious Diseases, 65(7), pp. 1226–1228. doi: 10.1093/cid/cix513.
  33. Palma, G. B. H. and Kaur, M. (2023) ‘miRNA-128 and miRNA-223 regulate cholesterol-mediated drug resistance in breast cancer’, IUBMB Life, 75(9), pp. 743–764. doi: 10.1002/iub.2726.
  34. Pan, H. et al. (2021) ‘Repurposed Antiviral Drugs for 沙巴体育官网_2024欧洲杯博彩app@ - Interim WHO Solidarity Trial Results.’, The New England journal of medicine, 384(6), pp. 497–511. doi: 10.1056/NEJMoa2023184.
  35. Pancera, M. et al. (2014) ‘Structure and immune recognition of trimeric pre-fusion HIV-1 Env.’, Nature, 514(7523), pp. 455–461. doi: 10.1038/nature13808.
  36. Pereira, L. et al. (2021) ‘African genetic diversity and adaptation inform a precision medicine agenda’, Nature Reviews Genetics, 22(5), pp. 284–306. doi: 10.1038/s41576-020-00306-8.
  37. Peters, J. S. et al. (2022) ‘Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response.’, Frontiers in cellular and infection microbiology, 12, p. 1064148. doi: 10.3389/fcimb.2022.1064148.
  38. Price, T. J. et al. (2014) ‘Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.’, The Lancet. Oncology, 15(6), pp. 569–579. doi: 10.1016/S1470-2045(14)70118-4.
  39. RECOVERY Collaborative Group (2022) ‘Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.’, Lancet (London, England), 400(10349), pp. 359–368. doi: 10.1016/S0140-6736(22)01109-6.
  40. Ruff, P., Speicher, D. W. and Husain-Chishti, A. (1991) ‘Molecular identification of a major palmitoylated erythrocyte membrane protein containing the src homology 3 motif.’, Proceedings of the National Academy of Sciences of the United States of America, 88(15), pp. 6595–6599. doi: 10.1073/pnas.88.15.6595.
  41. Ruff, P. et al. (2016) ‘Access to Cancer Therapeutics in Low- and Middle-Income Countries.’, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 35, pp. 58–65. doi: 10.1200/EDBK_155975.
  42. Ruff, P. et al. (2015) ‘Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.’, European journal of cancer (Oxford, England: 1990), 51(1), pp. 18–26. doi: 10.1016/j.ejca.2014.10.019.
  43. Ruff, P. et al. (2018) ‘Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.’, Journal of geriatric oncology, 9(1), pp. 32–39. doi: 10.1016/j.jgo.2017.07.010.
  44. Saha, S. T. et al. (2023) ‘2-Hydroxypropyl-&beta;-cyclodextrin (HP&beta;CD) as a Potential Therapeutic Agent for Breast Cancer’, Cancers, 15(10). doi: 10.3390/cancers15102828.
  45. Sengupta, D. et al. (2021) ‘Genetic substructure and complex demographic history of South African Bantu speakers’, Nature Communications, 12(1), p. 2080. doi: 10.1038/s41467-021-22207-y.
  46. Senzani, S. et al. (2017) ‘An Amidase_3 domain-containing N-acetylmuramyl-L-alanine amidase is required for mycobacterial cell division.’, Scientific reports, 7(1), p. 1140. doi: 10.1038/s41598-017-01184-7.
  47. Singh, E. et al. (2015) ‘Establishment of a cancer surveillance programme: the South African experience.’, The Lancet. Oncology, 16(8), pp. e414-21. doi: 10.1016/S1470-2045(15)00162-X.
  48. Thobakgale, C. F. et al. (2007) ‘Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants.’, Journal of virology, 81(23), pp. 12775–12784. doi: 10.1128/JVI.00624-07.
  49. Thobakgale, C. et al. (2017) ‘Interleukin 1-Beta (IL-1β) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients.’, Journal of acquired immune deficiency syndromes (1999), 74(2), pp. 213–220. doi: 10.1097/QAI.0000000000001181.
  50. Tumba, N. L. et al. (2022) ‘Covalent binding of human two-domain CD4 to an HIV-1 subtype C SOSIP.664 trimer modulates its structural dynamics’, Biochemical and Biophysical Research Communications, 612, pp. 181–187. doi: 10.1016/j.bbrc.2022.04.101
  51. Tumba, N. L. et al. (2022) ‘Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits’, Vaccine: X, 12, p. 100222. doi: https://doi.org/10.1016/j.jvacx.2022.100222.
  52. Van Cutsem, E. et al. (2009) ‘Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer’, New England Journal of Medicine, 360(14), pp. 1408–1417. doi: 10.1056/NEJMoa0805019.
  53. Van Cutsem, E. et al. (2011) ‘INTRAVENOUS (IV) AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH IRINOTECAN/5-FU (FOLFIRI) FOR SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A MULTINATIONAL PHASE III TRIAL (EFC10262-VELOUR).’, in, pp. v18–v18.
  54. Williams, L. D. et al. (2017) ‘Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.’, Science immunology, 2(7). doi: 10.1126/sciimmunol.aal2200.
  55. Wolter, N. et al. (2022) ‘Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa.’, Lancet (London, England). England, pp. 93–96. doi: 10.1016/S0140-6736(22)00981-3.
  56. Zilbauer, M. et al. (2023) ‘A Roadmap for the Human Gut Cell Atlas’, Nature Reviews Gastroenterology & Hepatology, 20(9), pp. 597–614. doi: 10.1038/s41575-023-00784-1.
Share